company background image
2L9 logo

Blueprint Medicines DB:2L9 Stock Report

Last Price

€86.78

Market Cap

€5.7b

7D

-1.4%

1Y

-11.0%

Updated

23 May, 2025

Data

Company Financials +

Blueprint Medicines Corporation

DB:2L9 Stock Report

Market Cap: €5.7b

2L9 Stock Overview

A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. More details

2L9 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 74.5% below our estimate of its fair value

Earnings are forecast to grow 61.45% per year

Risk Analysis

Significant insider selling over the past 3 months


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Blueprint Medicines Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Blueprint Medicines
Historical stock prices
Current Share PriceUS$86.78
52 Week HighUS$111.00
52 Week LowUS$67.54
Beta0.83
1 Month Change16.73%
3 Month Change-0.46%
1 Year Change-10.96%
3 Year Change65.36%
5 Year Change47.03%
Change since IPO236.10%

Recent News & Updates

Recent updates

Shareholder Returns

2L9DE BiotechsDE Market
7D-1.4%-1.4%-0.9%
1Y-11.0%-12.5%14.1%

Return vs Industry: 2L9 exceeded the German Biotechs industry which returned -13.4% over the past year.

Return vs Market: 2L9 underperformed the German Market which returned 15.8% over the past year.

Price Volatility

Is 2L9's price volatile compared to industry and market?
2L9 volatility
2L9 Average Weekly Movement7.0%
Biotechs Industry Average Movement5.7%
Market Average Movement6.5%
10% most volatile stocks in DE Market12.7%
10% least volatile stocks in DE Market3.1%

Stable Share Price: 2L9 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 2L9's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008685Kate Havilandwww.blueprintmedicines.com

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

Blueprint Medicines Corporation Fundamentals Summary

How do Blueprint Medicines's earnings and revenue compare to its market cap?
2L9 fundamental statistics
Market cap€5.70b
Earnings (TTM)-€137.09m
Revenue (TTM)€494.84m
11.7x
P/S Ratio
-42.1x
P/E Ratio

Is 2L9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2L9 income statement (TTM)
RevenueUS$562.12m
Cost of RevenueUS$19.77m
Gross ProfitUS$542.35m
Other ExpensesUS$698.08m
Earnings-US$155.73m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.41
Gross Margin96.48%
Net Profit Margin-27.70%
Debt/Equity Ratio185.4%

How did 2L9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 00:06
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Ishan MajumdarBaptista Research
Peter LawsonBarclays